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Summary
Background Genetic factors have a role in the pathogenesis of ischaemic stroke, but the main genes involved have yet 
to be deﬁ ned. Mitochondrial mechanisms have been implicated in the pathophysiology of acute stroke, but the role of 
mitochondrial DNA (mtDNA) has not been comprehensively studied. We investigated whether there is an association 
between mtDNA haplotypes and incidence of stroke.
Methods The major European mtDNA haplogroups were identiﬁ ed in two independent subpopulations (n=950) from 
a study of occurrence of transient ischaemic attack (TIA) and ischaemic stroke and were compared with those of 
patients with acute coronary syndromes from the same populations (n=340) and with those of independent population 
controls (n=2939). 
Findings The presence of mtDNA sub-haplogroup K was signiﬁ cantly less frequent in patients with TIA or stroke 
than in controls in both subpopulations separately and in a pooled analysis (odds ratio 0·54, 95% CI 0·39–0·75, 
p<0·00001). This association remained highly signiﬁ cant after adjustment for multiple haplogroup comparisons. The 
association was signiﬁ cant for patients with TIA and stroke separately and was independent of known risk factors, 
but was not found for patients with acute coronary events. The mtDNA sub-haplogroup K was present in 8·7% of the 
total UK population controls and therefore confers a 4·0% (95% CI 2·2–5·7) reduction in population attributable risk 
of TIA and stroke.
Interpretation Genetic variation of mtDNA sub-haplogroup K is an independent determinant of risk of cerebral, but 
not coronary, ischaemic vascular events. These ﬁ ndings implicate mitochondrial mechanisms in the aetiology of 
ischaemic stroke and provide a new means for the identiﬁ cation of individuals with a high susceptibility of developing 
ischaemic stroke.
Funding Medical Research Council UK, National Institute of Health Research (NIHR), the Stroke Association, the 
Dunhill Medical Trust, the NIHR-funded Oxford Biomedical Research Centre, the NIHR-funded Newcastle Biomedical 
Research Centre in Ageing, and the Wellcome Trust. 
Introduction
Ischaemic stroke is a major cause of severe disability 
and premature death. Hypertension, hyperlipidaemia, 
diabetes, and smoking are all risk factors for stroke, but 
do not account for all of the risk.1 Findings from twin and 
family studies lend support to a role for inherited factors 
in both transient ischaemic attack (TIA) and ischaemic 
stroke,2 even after the exclusion of known monogenic 
causes, and a complex interplay between environmental 
and inherited factors is likely.3 Heritability of stroke seems 
to be greater in women than in men, with a two-fold excess 
of maternal versus paternal stroke in female probands but 
not in male probands.4 This diﬀ erence could be caused by 
epigenetic or environmental factors, but is also consistent 
with a maternally transmitted risk allele. However, most 
genetic studies done so far in patients with stroke have 
focused on the nuclear genome, including several genome-
wide association studies.5–7 Few studies have investigated 
the role of mitochondrial DNA (mtDNA), which is almost 
exclusively maternally inherited and could therefore 
account for the recent genetic epidemiological ﬁ ndings. 
mtDNA is an appealing candidate for heritability of 
stroke for several other reasons. Pathogenetic mutations 
of mtDNA cause a maternally inherited mitochondrial 
disease characterised by stroke-like episodes (mito-
chondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes) associated with biochemical and 
structural abnormalities of the cerebral vasculature.8 
Patients carrying speciﬁ c mtDNA point mutations are 
prone to stroke in the occipital regions. Additionally, 
genetic variation of mtDNA has been associated with 
several risk factors for ischaemic stroke, including 
hypertension,9 type 2 diabetes,10 increased LDL 
concentrations,11 obesity,12 and the metabolic syndrome.13 
mtDNA has accumulated polymorphic variants, or 
single nucleotide polymorphisms (SNPs), throughout 
human history. In the absence of biparental re-
combination, these SNPs form branches of an evolving 
phylogenetic tree. The major subdivisions of the global 
mtDNA phylogeny occurred more than 10 000 years 
ago and are called mtDNA haplogroups. These 
haplogroups developed as human beings migrated into 
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new geographic regions, leading to region-speciﬁ c 
haplogroup variation. More than 95% of Europeans 
belong to one of ten major haplogroups, H, J, T, U, K (a 
subgroup of U), M, I, V, W, and X. Each haplogroup 
deﬁ nes a clade of related mtDNAs that contains speciﬁ c 
sequence variants within the population. mtDNA 
haplogroups aﬀ ect the assembly and stability of the 
mitochondrial respiratory chain14 and the propensity to 
develop oxygen free radicals,15 which are implicated in 
the pathophysiology of ischaemic stroke. 
Data from several small studies have indicated an 
association between diﬀ erent mtDNA haplogroups and 
diﬀ erent forms of ischaemic stroke;16–18 however, only one 
study included more than 500 individuals,16 none have 
replicated their ﬁ ndings in a separate cohort, and none 
fully accounted for potential confounding factors by 
intermediate phenotypes, particularly premorbid blood 
pressure. We investigated the mtDNA haplogroup 
distribution in two independent UK cohorts of patients 
with TIA or ischaemic stroke and compared them with 
healthy control individuals and patients with acute 
coronary syndromes, which share major risk factors with 
ischaemic stroke. 
Methods 
Participants
This case-control study included two independent disease 
cohorts and several independent control groups of white 
individuals within the UK.
The primary disease group included patients from the 
Oxford Vascular Study (OXVASC), a population-based 
study of patients with acute vascular events, including 
patients with TIAs, strokes, and acute coronary 
syndromes.19 This subpopulation was derived from two 
distinct populations: individuals resident in Oxford city 
and individuals resident in surrounding towns and 
villages in Oxfordshire. 
The methods of OXVASC and details of the study 
populations have been reported previously.19 Brieﬂ y, all 
cases of TIA, ischaemic stroke or acute coronary 
syndrome were ascertained from an overall population of 
91 000 individuals, irrespective of age, who were registered 
with 63 primary care physicians in four primary care 
practices in Oxford and in ﬁ ve practices in the 
surrounding towns and villages in Oxfordshire, UK. In 
the UK, almost all individuals register with a primary 
care practice, which holds a lifelong medical record. 
OXVASC was approved by a local research ethics 
committee and began on April 1, 2002, after a 3-month 
pilot study to ensure reliable case ascertainment. All 
patients with acute vascular events in the OXVASC 
population were identiﬁ ed by several overlapping 
methods, including prospective daily searches for acute 
events in hospital wards and clinics and retrospective 
searches of hospital and primary care administrative and 
diagnostic coding data. Direct assessment of ascertain-
ment has shown it to be complete.19
Patients were eligible for inclusion in the present study 
if they had had a deﬁ nite TIA or stroke (ie, cases) or an ST-
elevation acute myocardial infarction (ie, disease controls) 
between April 1, 2002, and March 31, 2007. Patients were 
assessed by a study physician as soon as possible after the 
event in a hospital ward or in an outpatient clinic. 
Informed consent was sought, where possible, or assent 
was obtained from a relative. Clinical history, examination, 
and recording of investigations were standardised. Severity 
of stroke was assessed with the National Institutes of 
Health stroke scale (NIHSS). All cases were reviewed by 
the senior neurologist of the study (PMR) and classiﬁ ed as 
TIA, stroke, or other disorder by use of standard 
deﬁ nitions.19 Patients were followed up by a research nurse 
or a clinical research fellow after 1, 6, 12, 24, and 60 months 
and were asked about any symptoms of recurrent 
ischaemic events. Recovery after stroke was assessed at 
these timepoints with the modiﬁ ed Rankin scale. All 
recurrent vascular events that presented to medical 
attention were also identiﬁ ed acutely by the continuing 
case ascertainment in the OXVASC study. Inpatients who 
moved out of the area were followed up by telephone. 
If a recurrent vascular event was suspected at a follow-
up visit or on reascertainment in OXVASC, the patient 
was reassessed and investigated by a study physician. 
The deﬁ nitions of recurrent TIA and stroke used in 
OXVASC have been reported previously,20 and required a 
sudden new symptomatic neurological deterioration on a 
background of stability or improvement after the 
presenting event. Acute coronary events were deﬁ ned by 
use of published criteria21 on the basis of history, 
electrocardiographic ﬁ ndings, cardiac biomarkers, 
autopsy, or death certiﬁ cate. Troponin-I concentrations 
were measured with the Bayer Centaur assay, using the 
manufacturer’s normal range (Bayer Healthcare 
Diagnostics Division, Tarrytown, NY, USA). 
Procedures and statistical analysis
The major European haplogroups were genotyped in ﬁ ve 
multiplexed allele-speciﬁ c primer extension reactions by 
use of matrix-associated laser desorption/ionisation time 
of ﬂ ight mass spectrometry (MALDITOF; MassARRAY, 
Sequenom, San Diego, CA, USA; webappendix) as 
described.22 5% of the samples were randomly selected 
for conﬁ rmatory genotyping by use of a standard 
restriction enzyme approach,23 which yielded 100% 
concordance. 
Haplogroup frequencies were compared by use of 
Fisher’s exact test, and odds ratios with conﬁ dence 
intervals were calculated. The relation between the other 
variables and the haplogroups was studied by use of 
logistic regression analysis.
We initially compared the frequency of the major 
mtDNA haplogroups with the type of vascular event: TIA 
or ischaemic stroke (cases) versus ST-elevation acute 
myocardial infarction (disease controls). If patients with 
TIA or stroke had a previous myocardial infarction or 
See Online for webappendix
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had a myocardial infarction during follow-up they were 
included in the analysis as a TIA or a stroke case. Patients 
with myocardial infarction who had a history of stroke 
before the study period were not excluded.
We also compared the genotype frequencies with two 
ethnically matched UK control groups. The ﬁ rst group 
included 1500 healthy control individuals—1010 from the 
UK Medical Research Council 1958 birth cohort; 344 healthy 
neonates from north Cumbria, UK, and 146 healthy adult 
controls without previous TIA or stroke, recruited as part 
of the OXVASC study. The second group included 
1439 disease control individuals—939 patients with type 2 
diabetes from the Diabetes UK Warren 2 cohort,24 and 
500 patients with amyotrophic lateral sclerosis.25 The 
haplogroup frequency of these two disease control groups 
did not diﬀ er from that of the general population.24 
We ﬁ rst analysed all cases (ie, patients with TIA, stroke, 
or acute coronary syndromes) and controls from the 
Oxford subpopulation and then tested any associations in 
the Oxfordshire subpopulation. Any associations of 
speciﬁ c haplotypes with TIA and ischaemic stroke that 
were signiﬁ cant in both subpopulations were then related 
to additional potentially relevant baseline and outcome 
data collected from the patients with TIA or ischaemic 
stroke: TIA versus stroke at baseline, age at ﬁ rst stroke, 
sex, diabetes, hypertension, atrial ﬁ brillation, migraine, 
nature of the presenting event (stroke vs TIA), stroke 
severity (NIHSS score) at ﬁ rst assessment, aﬀ ected 
vascular territory (anterior vs posterior circulation, 
brainstem vs occipital lobe), aetiological subtype of TIA or 
ischaemic stroke (classiﬁ cation from the Trial of 
Org 10172 in Acute Stroke Treatment [TOAST]), the main 
intermediate phenotypes (extent of symptomatic or 
asymptomatic carotid stenosis), leukoaraiosis on CT brain 
imaging, total cholesterol concentration at entry, stroke 
recovery (Rankin score at 6 months of follow-up), and the 
risk of recurrent stroke. A detailed record of family history 
of any acute vascular events in all ﬁ rst-degree relatives 
was obtained from the patient and/or relatives. 
Given the strength of the epidemiological association 
between hypertension and risk of stroke,26 and the 
evidence of eﬀ ects of mutations in mtDNA on blood 
pressure,16 we investigated any potential confounding of 
apparent genetic associations by blood pressure in 
particular detail. All premorbid measurements of blood 
pressure during the previous 10 years were extracted 
from primary care and hospital records for all patients 
with TIA or stroke in the OXVASC study and the following 
variables were calculated: mean, maximum, minimum, 
and standard deviation. Blood pressure was also measured 
at the time of the TIA or stroke and at 1, 6, and 12 months 
of follow-up. Analyses were done with and without 
stratiﬁ cation by antihypertensive medication. 
Role of the funding source
The funding sources had no role in the study design, in 
the collection, analysis, or interpretation of the data, or in 
the writing of the report. PMR had full access to all the 
data in the study. PMR and PFC had ﬁ nal responsibility 
for the decision to submit for publication. 
Results
1282 patients had TIA or stroke in the overall OXVASC 
population, of whom 1199 (723 stroke, 476 TIA) survived 
to clinical assessment and consented to providing a blood 
sample. 950 individuals had suﬃ  cient quality and 
quantity of DNA available for testing. Of 411 patients 
ascertained to have acute ST-elevation myocardial 
infarction, 386 consented to providing a blood sample, 
and DNA was available in 340 individuals. There were no 
signiﬁ cant diﬀ erences in the type or severity of TIA or 
stroke, nor in the vascular risk factors, between the 
patients for whom a DNA sample was available and those 
for whom no DNA sample was available. Thus, the 
incomplete ascertainment of DNA samples was highly 
unlikely to have aﬀ ected the ﬁ ndings of this study. 
In the Oxford city subpopulation, the frequency of sub-
haplogroup K was signiﬁ cantly lower in patients with 
TIA or stroke than in patients with acute coronary 
syndromes (p=0·0098), healthy UK controls (p=0·0082), 
and the combined control cohort of healthy and disease 
controls (p=0·0066). The frequency of all other major 
haplogroups did not diﬀ er signiﬁ cantly between patients 
with TIA or stroke and controls (table 1), including a 
comparison of the combined group of the rarer 
haplogroups I, W, V, X, M with other rare European and 
non-European haplogroups (p=0·96). In the Oxfordshire 
county subpopulation, we observed a similarly low 
frequency of sub-haplogroup K in patients with TIA or 
stroke compared with patients with acute coronary 
syndromes (p=0·049), healthy UK controls (p=0·0034), 
and the combined cohort of healthy and disease controls 
(p=0·0022). Combination of both OXVASC sub-
populations increased the strength of the association; the 
frequency of sub-haplogroup K in patients with TIA or 
stroke was about half that in patients with acute coronary 
syndromes (p=0·0016), healthy UK controls (p=0·0002), 
and the combined cohort of healthy and disease controls 
(odds ratio 0·54, 95% CI 0·39–0·75, p<0·0001; table 2). 
The frequency of sub-haplogroup K in patients with TIA 
and in patients with stroke was signiﬁ cantly lower than 
in the UK population controls, but the frequencies of all 
other major haplogroups did not diﬀ er from the 
frequencies in controls (table 1).
In logistic regression analyses, we found no signiﬁ cant 
associations between the frequency of sub-haplogroup K 
and any of the following baseline characteristics: age at 
ﬁ rst TIA or stroke, sex, diabetes, hypertension, atrial 
ﬁ brillation, migraine, and previous use of aspirin or 
statins. There was also no signiﬁ cant heterogeneity in 
the association in relation to stroke severity (NIHSS score 
at ﬁ rst assessment), the aﬀ ected vascular territory 
(anterior vs posterior circulation; brainstem vs occipital 
lobe), the aetiogical subtype of ischaemic stroke (TOAST 
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classiﬁ cation), or the main intermediate phenotypes 
(extent of symptomatic or asymptomatic carotid stenosis, 
leukoaraiosis on CT brain imaging, or total cholesterol 
concentration at entry). Frequency of sub-haplotype K 
was also unrelated to stroke recovery (Rankin score at 
6 months’ follow-up).
Among patients with TIA or stroke, sub-haplogroup K 
was not signiﬁ cantly associated with systolic or diastolic 
blood pressure at the time of ﬁ rst assessment: mean 
(SD) systolic blood pressure for patients with sub-
haplogroup K was 152·3 mm Hg (26·3) versus 
156·1 mm Hg (29·7) for patients with other sub-
haplotypes (p=0·38), and mean (SD) diastolic blood 
pressure was 84·1 mm Hg (13·7) for those with sub-
haplogroup K versus 84·5 mm Hg (14·7) for those with 
other sub-haplotypes (p=0·83). Both groups had an 
average of 18 premorbid blood pressure measurements, 
but there were no signiﬁ cant diﬀ erences in mean 
systolic or mean diastolic blood pressure, or in 
minimum, maximum, or SD systolic or diastolic blood 
pressure. For example, mean (SD) premorbid systolic 
blood pressure in individuals with sub-haplogroup K 
was 144·3 mm Hg (13·1) versus 147·4 mm Hg (15·6) in 
individuals with the other sub-haplotypes (p=0·18). 
There were also no diﬀ erences in systolic or diastolic 
blood pressure on follow-up. Stratiﬁ cation of these 
analyses by use of antihypertensive drugs did not reveal 
any signiﬁ cant diﬀ erences between mtDNA haplotypes. 
To assess the eﬀ ect of sub-haplogroup K at the 
population level, we determined the population 
attributable risk, which depends on the relative risk of 
sub-haplogroup K and the proportion of the population 
who carry sub-haplogroup K.27 Based on the data we 
present here, the reduction in population attributable 
risk of TIA and ischaemic stroke conferred by sub-
haplogroup K is 4·0% (95% CI 2·2–5·7). 
Discussion
Our ﬁ ndings show a strong association between mtDNA 
sub-haplogroup K and reduced risk of TIA and 
ischaemic stroke in the UK population. This association 
is not present in patients with acute coronary syndromes 
and was not explained by confounding by blood 
pressure or other intermediate phenotypes. This result 
is consistent with the hypothesis that genetic variation 
of mtDNA is a risk factor speciﬁ cally for cerebral 
ischaemic events that are independent of the known 
major vascular risk factors. 
How should we interpret our ﬁ ndings, given the growing 
amount of publications associating diﬀ erent mtDNA 
haplogroups with many complex traits? First, our initial 
association was conﬁ rmed in a second subpopulation, was 
present both in patients with TIA and in patients with 
ischaemic stroke, and was based on a comparison with 
several control groups, thus reducing the likelihood of a 
false-positive result. Second, disease controls with an 
acute coronary syndrome were collected in parallel, did 
not show the association of the haplotype with disease, 
and had a genotype distribution indistinguishable from 
2939 UK controls. Third, we conﬁ rmed the ﬁ ndings of the 
largest previous studies, which did not identify an 
association between mtDNA haplogroups and ischaemic 
heart disease, hypertension, diabetes, or other features of 
the metabolic syn drome.28 Fourth, the diﬀ erence in the 
frequency of sub-haplogroup K remained highly 
signiﬁ cant even after a conservative Bonferroni correction 
for the multiple signiﬁ cance testing for the 12 diﬀ erent 
groups of European mtDNAs. Fifth, logistic regression 
analysis showed that the association was independent of 
known major cerebrovascular risk factors, despite 
extracting particularly detailed data on premorbid blood 
pressure—the strongest risk factor for TIA and stroke. 
Finally, our ﬁ ndings are in agreement with those of a 
H T J  U K* I W V X M Other† Total
Cases
Oxford city subpopulation
TIA or stroke 215 (45·8%) 48 (10·2%) 42 (9·0%) 75 (16·0%) 24 (5·1%) 9 (1·9%) 14 (3·0%) 26 (5·5%) 6 (1·3%) 0 (0%) 10 (2·1%) 469
ACS 56 (35·2%) 21 (13·2%) 17 (10·7%) 27 (17·0%) 18 (11·3%) 1 (0·6%) 2 (1·3%) 4 (2·5%) 1 (0·6%) 8 (5·0%) 4 (2·5%) 159
Oxfordshire subpopulation
TIA or stroke 225 (46·8%) 50 (10·4%) 53 (11·0%) 72 (15·0%) 23 (4·8%) 8 (1·7%) 10 (2·1%) 23 (4·8%) 9 (1·9%) 1 (0·2%) 7 (1·5%) 481
ACS 82 (45·3%) 20 (11·1%) 16 (8·8%) 26 (14·4%) 16 (8·8%) 2 (1·1%) 3 (1·7%) 4 (2·2%) 1 (0·6%) 9 (5·0%) 2 (1·1%) 181
OXVASC total  
TIA or stroke 440 (46·3%) 98 (10·3%) 95 (10·0%) 147 (15·5%) 47 (5·0%) 17 (1·8%) 24 (2·5%) 49 (5·2%) 15 (1·6%) 1 (0·1%) 17 (1·8%) 950
ACS 138 (40·6%) 41 (12·1%) 33 (9·7%) 53 (15·6%) 34 (10·0%) 3 (0·9%) 5 (1·5%) 8 (2·4%) 2 (0·6%) 17 (5·0%) 6 (1·8%) 340
Controls
Healthy UK controls 642 (42·8%) 157 (10·5%) 162 (10·8%) 187 (12·5%) 133 (8·9%) 43 (2·9%) 27 (1·8%) 54 (3·6%) 22 (1·5%) 16 (1·1%) 57 (3·8%) 1500
Disease controls 650 (45·2%) 129 (9·0%) 175 (12·2%) 202 (14·0%) 124 (8·6%) 34 (2·4%) 27 (1·9%) 37 (2·6%) 27 (1·9%) 1 (0·1%) 33 (2·3%) 1439
Total controls 1292 (44·0%) 286 (9·7%) 337 (11·5%) 389 (13·2%) 257 (8·7%) 77 (2·6%) 54 (1·8%) 91 (3·1%) 49 (1·7%) 17 (0·6%) 90 (3·1%) 2939
Data are n (%). OXVASC=Oxford Vascular Study. TIA=transient ischaemic attack. ACS=acute coronary syndrome. *Haplogroup K is a subtype of U. The haplogroup U data do not include the K subgroup. †Rare 
European and non-European haplogroups. Some numbers were rounded so not all percentages total 100%. 
Table 1: Frequency of the major European mitochondrial DNA haplogroups in the OXVASC study population and in controls
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previous phylogenetic study that identiﬁ ed clusters of 
sub-haplogroup K in 14 patients with occipital stroke.18 
Furthermore, our data also complement two single-
cohort studies: one in Japan17 for the eastern Asian 
haplogroup A, which is not present in European 
populations, and another in Portugal for the sub-
haplogroup H1.16 This study was designed to investigate 
all of haplogroup H, and did not select speciﬁ c subgroups 
such as H1.  
Although data from a Danish study of 9254 individuals 
showed no association between haplogroup K1 and stroke 
or cardiovascular disease,29 only 439 of the participants 
had an ischaemic stroke, based on case-notes review. The 
phenotyping in our 950 study patients with TIA or 
ischaemic stroke was based on the direct clinical 
assessment of each case by the study team, using 
established diagnostic criteria and with a 95% rate of 
brain imaging or autopsy.19 Greater statistical power and 
diagnostic accuracy in our study than in the Danish study 
could possibly explain the discrepancy.
Given the epidemiological evidence of an increased 
risk of stroke among maternal relatives,4 we were 
surprised not to ﬁ nd an association between the maternal 
history of stroke and sub-haplogroup K. However, a meta-
analysis of sex diﬀ erences in heritability of ischaemic 
stroke4 showed that the risk of stroke is greater in the 
sisters of women with stroke than in the brothers of 
women with stroke, despite the fact that all siblings share 
the same mtDNA inherited from their mother. Thus, 
both the genetic data from this study (data not presented 
here), and previously published epidemiological data,4 
indicate that the increased heritability of stroke in women 
is not likely to be exclusively mediated through mtDNA. 
Other explanations for the gender bias include sex-
speciﬁ c autosomal genetic factors, epigenetic, or non-
genetic mechanisms.4
Previous studies have shown a decreased frequency of 
sub-haplogroup K in patients with idiopathic Parkinson’s 
disease.30,31 This association with the sub-haplotype K 
seemed to be speciﬁ c to Parkinson’s disease,32 suggesting 
that the association was not mediated through a common 
neurodegenerative process. Similarly, we saw no 
association with severity of stroke or with propensity for 
post-stroke recovery. This ﬁ nding suggests that the 
mtDNA haplogroup eﬀ ect in stroke is mediated through 
the pathophysiology of the acute event itself, independent 
of blood cholesterol concentration, diabetes, blood 
pressure, age, or sex. How could this occur? 
There is emerging evidence indicating the functional 
consequences of mtDNA haplogroup variation at the 
biochemical level. Neutral genetic variants in mice are 
associated with increased production of reactive oxygen 
species,33 and mtDNA haplogroups in human beings 
modulate the assembly kinetics of mitochondrial 
respiratory chain proteins.14 This idea provides an 
explanation for the increased risk of visual failure in 
individuals with Leber’s hereditary optic neuropathy, 
which is also linked to increased production of reactive 
oxygen species.34 Both mitochondrial dysfunction and 
oxidative stress contribute to vascular endothelial 
senescence35 and atherosclerosis.36 If this is the 
mechanism underpinning the haplogroup association 
we describe here, we cannot explain why the eﬀ ect is 
speciﬁ c for cerebrovascular disease. Moreover, further 
work is required to deﬁ ne the precise genetic variants or 
cluster of variants that give rise to the reduced risk of TIA 
and ischaemic stroke conferred by sub-haplogroup K and 
the precise mechanism of action.
Recent genome-wide association studies have not yet 
identiﬁ ed new genes associated with ischaemic stroke. A 
few SNPs have only fairly weak associations, with odds 
ratios conferring less risk than mtDNA sub-haplogroup K. 
Our ﬁ ndings indicate the importance of mtDNA as a 
genetic risk factor for stroke, adding weight to the 
growing body of evidence implicating mitochondrial 
mechanisms in the pathophysiology of the disorder, and 
providing a means to identify individuals at risk of 
ischaemic stroke in the general population.
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Odds ratio 95% CI
H 1·10 0·95–1·27
T 1·07 0·84–1·36
J 0·86 0·67–1·09
U 1·20 0·98–1·47
K* 0·54 0·39–0·75
I 0·68 0·40–1·15
W 1·38 0·85–2·25
V 1·70 1·19–2·43
X 0·95 0·53–1·70
M 0·18 0·02–1·36
Other† 0·58 0·33–1·00
Odds ratios were calculated from 950 cases and 2939 controls. *Haplogroup K is 
a subtype of U. The data for the haplogroup U do not include the K subgroup. 
†Non-European haplogroups. 
Table 2: European mitochondrial DNA haplogroups in the total OXVASC 
study population with acute transient ischaemic attack or stroke 
versus controls
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